Brief: Axovant Announces Positive SixMonth FollowUp Data From Second Cohort Of SunrisePd Phase 2 Trial Of AxoLentiPd Gene Therapy

Sio Gene Therapies

06/10/2020 12:05

Oct 6 (Reuters) - Axovant Gene Therapies Ltd  AXGT.O :
    * AXOVANT ANNOUNCES POSITIVE SIX-MONTH FOLLOW-UP DATA FROM
SECOND
COHORT OF SUNRISE-PD PHASE 2 TRIAL OF AXO-LENTI-PD GENE THERAPY
    * AXOVANT GENE THERAPIES LTD - AXO-LENTI-PD WAS
WELL-TOLERATED
WITH NO TREATMENT-RELATED SERIOUS ADVERSE EVENTS AT 6 MONTHS
    * AXOVANT GENE THERAPIES LTD - EXPLORE-PD, A RANDOMIZED,
SHAM-CONTROLLED STUDY OF AXO-LENTI-PD IS EXPECTED TO BEGIN
DOSING IN 2021
    * AXOVANT GENE THERAPIES LTD - TWO EVALUABLE PATIENTS IN
COHORT 2
AXO-LENTI-PD STUDY SHOWED A 21-POINT MEAN IMPROVEMENT IN UPDRS
PART III "OFF" SCORE

Source text for Eikon:  ID:nGNX3dyqmm 
Further company coverage:  AXGT.O 

 ((Reuters.Briefs@thomsonreuters.com;))